Published in Ann Oncol on March 21, 2013
Targeting the mTOR pathway in hepatocellular carcinoma: current state and future trends. J Hepatol (2013) 1.22
Epigenetics in hepatocellular carcinoma: an update and future therapy perspectives. World J Gastroenterol (2014) 1.00
Current clinical regulation of PI3K/PTEN/Akt/mTOR signalling in treatment of human cancer. J Cancer Res Clin Oncol (2014) 0.96
Oxidative stress and hepatic Nox proteins in chronic hepatitis C and hepatocellular carcinoma. Free Radic Biol Med (2014) 0.94
Sorafenib-based combined molecule targeting in treatment of hepatocellular carcinoma. World J Gastroenterol (2015) 0.87
A phase II trial of bevacizumab plus temsirolimus in patients with advanced hepatocellular carcinoma. Invest New Drugs (2014) 0.84
Microtubule-targeting agents in oncology and therapeutic potential in hepatocellular carcinoma. Onco Targets Ther (2014) 0.82
mTOR in viral hepatitis and hepatocellular carcinoma: function and treatment. Biomed Res Int (2014) 0.82
Circulating tumor cells in hepatocellular carcinoma: a pilot study of detection, enumeration, and next-generation sequencing in cases and controls. BMC Cancer (2015) 0.82
Dosing de novo combinations of two targeted drugs: Towards a customized precision medicine approach to advanced cancers. Oncotarget (2016) 0.81
Management of recurrent hepatocellular carcinoma after liver transplant. World J Hepatol (2015) 0.81
Combination treatment including targeted therapy for advanced hepatocellular carcinoma. Oncotarget (2016) 0.79
Development of systemic therapy for hepatocellular carcinoma at 2013: updates and insights. World J Gastroenterol (2014) 0.78
Combined treatment with silibinin and either sorafenib or gefitinib enhances their growth-inhibiting effects in hepatocellular carcinoma cells. Clin Mol Hepatol (2015) 0.78
Phase I/II study of temsirolimus for patients with unresectable Hepatocellular Carcinoma (HCC)- a correlative study to explore potential biomarkers for response. BMC Cancer (2015) 0.77
Precision medicine for hepatocellular carcinoma: driver mutations and targeted therapy. Oncotarget (2017) 0.75
Sorafenib in advanced hepatocellular carcinoma: current status and future perspectives. J Hepatocell Carcinoma (2014) 0.75
Recent Advances in the Development of Antineoplastic Agents Derived from Natural Products. Drugs (2015) 0.75
Inefficiencies and Patient Burdens in the Development of the Targeted Cancer Drug Sorafenib: A Systematic Review. PLoS Biol (2017) 0.75
Combination of Photon and Carbon Ion Irradiation with Targeted Therapy Substances Temsirolimus and Gemcitabine in Hepatocellular Carcinoma Cell Lines. Front Oncol (2017) 0.75
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer (2009) 77.71
Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) 54.30
Management of hepatocellular carcinoma: an update. Hepatology (2011) 33.57
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol (2008) 23.93
Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol (2004) 5.12
Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology (2008) 4.03
Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist (2007) 3.42
New utility of an old marker: serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy. J Clin Oncol (2008) 2.65
Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. J Hepatol (2009) 2.42
Characterization of circulating tumor cell aggregates identified in patients with epithelial tumors. Phys Biol (2012) 2.02
Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301. J Clin Oncol (2009) 1.75
Phase 1/2 study of everolimus in advanced hepatocellular carcinoma. Cancer (2011) 1.59
Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma. J Hepatol (2012) 1.57
Vascular remodeling and antitumoral effects of mTOR inhibition in a rat model of hepatocellular carcinoma. J Hepatol (2007) 1.56
Chronic activation of mTOR complex 1 is sufficient to cause hepatocellular carcinoma in mice. Sci Signal (2012) 1.50
The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma. Med Oncol (2009) 1.46
Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma. Clin Cancer Res (2008) 1.40
Sorafenib and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma. J Cell Mol Med (2009) 1.30
Utility of Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxy prothrombin, alone or in combination, as biomarkers for hepatocellular carcinoma. Clin Gastroenterol Hepatol (2008) 1.26
Early decrease in α-fetoprotein, but not des-γ-carboxy prothrombin, predicts sorafenib efficacy in patients with advanced hepatocellular carcinoma. Oncology (2011) 1.24
RAD001 (everolimus) inhibits tumour growth in xenograft models of human hepatocellular carcinoma. J Cell Mol Med (2008) 1.19
Sirolimus-based immunosuppression in liver transplantation for hepatocellular carcinoma: a meta-analysis. Liver Transpl (2012) 1.18
Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation. Liver Transpl (2012) 1.16
PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation. J Surg Res (2011) 1.15
Phase I study of the combination of sorafenib and temsirolimus in patients with metastatic melanoma. Clin Cancer Res (2012) 1.11
Safety and Efficacy of Sorafenib in Patients with Hepatocellular Carcinoma (HCC) and Child-Pugh A versus B Cirrhosis. Gastrointest Cancer Res (2011) 1.10
A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma. Cancer (2011) 1.08
Everolimus augments the effects of sorafenib in a syngeneic orthotopic model of hepatocellular carcinoma. Mol Cancer Ther (2011) 1.06
Activation of PI3K/AKT and MAPK pathway through a PDGFRβ-dependent feedback loop is involved in rapamycin resistance in hepatocellular carcinoma. PLoS One (2012) 1.05
Randomized phase II trial of sorafenib with temsirolimus or tipifarnib in untreated metastatic melanoma (S0438). Clin Cancer Res (2012) 1.04
Two drug interaction studies of sirolimus in combination with sorafenib or sunitinib in patients with advanced malignancies. Clin Cancer Res (2011) 0.95
Sirolimus inhibits the growth and metastatic progression of hepatocellular carcinoma. J Cancer Res Clin Oncol (2008) 0.95
ABT-869, a multi-targeted tyrosine kinase inhibitor, in combination with rapamycin is effective for subcutaneous hepatocellular carcinoma xenograft. J Hepatol (2008) 0.91
Phase II study of sirolimus in treatment-naive patients with advanced hepatocellular carcinoma. Dig Liver Dis (2012) 0.91
The role of PI3K/mTOR inhibition in combination with sorafenib in hepatocellular carcinoma treatment. Anticancer Res (2012) 0.88
Bacterial infections other than spontaneous bacterial peritonitis in cirrhosis. World J Hepatol (2012) 0.87
HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature (1996) 20.59
Robust perfect adaptation in bacterial chemotaxis through integral feedback control. Proc Natl Acad Sci U S A (2000) 7.67
Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med (1999) 7.04
Hyperpolarizing vasodilators activate ATP-sensitive K+ channels in arterial smooth muscle. Science (1989) 5.60
Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med (2001) 5.22
Indium phosphide nanowires as building blocks for nanoscale electronic and optoelectronic devices. Nature (2001) 5.09
A genetic map and recombination parameters of the human malaria parasite Plasmodium falciparum. Science (1999) 4.75
In vivo evidence of structural brain asymmetry in musicians. Science (1995) 4.71
Crystal structures of human topoisomerase I in covalent and noncovalent complexes with DNA. Science (1998) 4.51
Electrostatic interactions of S4 voltage sensor in Shaker K+ channel. Neuron (1995) 4.49
Identification of a chlamydial protease-like activity factor responsible for the degradation of host transcription factors. J Exp Med (2001) 4.27
Separation of human breast cancer cells from blood by differential dielectric affinity. Proc Natl Acad Sci U S A (1995) 4.00
Nucleotide sequence of the G protein gene of human respiratory syncytial virus reveals an unusual type of viral membrane protein. Proc Natl Acad Sci U S A (1985) 3.93
Imaging human mesolimbic dopamine transmission with positron emission tomography: I. Accuracy and precision of D(2) receptor parameter measurements in ventral striatum. J Cereb Blood Flow Metab (2001) 3.31
Proton-pump inhibitors and risk of fractures: an update meta-analysis. Osteoporos Int (2016) 3.30
Efficacies of different preparations of glucosamine for the treatment of osteoarthritis: a meta-analysis of randomised, double-blind, placebo-controlled trials. Int J Clin Pract (2013) 3.16
A chemokine receptor CCR2 allele delays HIV-1 disease progression and is associated with a CCR5 promoter mutation. Nat Med (1998) 3.15
A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am J Transplant (2009) 3.09
Multiple DNA fragment polymorphisms associated with immunoglobulin mu chain switch-like regions in man. Proc Natl Acad Sci U S A (1983) 3.07
Structure at 0.85 A resolution of an early protein photocycle intermediate. Nature (1998) 2.98
Multiple drug-resistant human KB carcinoma cells independently selected for high-level resistance to colchicine, adriamycin, or vinblastine show changes in expression of specific proteins. J Biol Chem (1986) 2.93
Functional domains of Pseudomonas exotoxin identified by deletion analysis of the gene expressed in E. coli. Cell (1987) 2.93
Automated analysis of protein NMR assignments using methods from artificial intelligence. J Mol Biol (1997) 2.86
A cardiac myocyte vascular endothelial growth factor paracrine pathway is required to maintain cardiac function. Proc Natl Acad Sci U S A (2001) 2.77
Physicochemical foundations and structural design of hydrogels in medicine and biology. Annu Rev Biomed Eng (2000) 2.73
Use of allelic loss to predict malignant risk for low-grade oral epithelial dysplasia. Clin Cancer Res (2000) 2.71
High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis (1996) 2.70
Mediation of tubuloglomerular feedback by adenosine: evidence from mice lacking adenosine 1 receptors. Proc Natl Acad Sci U S A (2001) 2.65
Changes in Friend murine erythroleukaemia cell membranes during induced differentiation determined by electrorotation. Biochim Biophys Acta (1994) 2.65
Pathway leading to correctly folded beta-tubulin. Cell (1996) 2.55
Impact of number of nodes retrieved on outcome in patients with rectal cancer. J Clin Oncol (2001) 2.54
PET imaging of serotonin 1A receptor binding in depression. Biol Psychiatry (1999) 2.48
Apolipoprotein E: from atherosclerosis to Alzheimer's disease and beyond. Curr Opin Lipidol (1999) 2.48
HIV-1 subtype and second-receptor use. Nature (1996) 2.46
Case study of the effects of atmospheric aerosols and regional haze on agriculture: an opportunity to enhance crop yields in China through emission controls? Proc Natl Acad Sci U S A (1999) 2.44
Proteolytic activation of protein kinase C delta by an ICE/CED 3-like protease induces characteristics of apoptosis. J Exp Med (1996) 2.42
Prevalence and magnitude of perinatal substance exposures in California. N Engl J Med (1993) 2.42
Pluripotency factors Lin28 and Oct4 identify a sub-population of stem cell-like cells in ovarian cancer. Oncogene (2010) 2.42
Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations. J Natl Cancer Inst (1999) 2.41
Arterial dilations in response to calcitonin gene-related peptide involve activation of K+ channels. Nature (1990) 2.39
A novel RNA-binding motif in influenza A virus non-structural protein 1. Nat Struct Biol (1997) 2.16
Cell separation by dielectrophoretic field-flow-fractionation. Anal Chem (2000) 2.13
The effects of sodium ions and potassium ions on glycine uptake by mouse ascites-tumour cells in the presence and absence of selected metabolic inhibitors. Biochem J (1967) 2.09
Discovery of small-molecule inhibitors of Bcl-2 through structure-based computer screening. J Med Chem (2001) 2.06
A new focal adhesion protein that interacts with integrin-linked kinase and regulates cell adhesion and spreading. J Cell Biol (2001) 2.04
Theaflavins in black tea and catechins in green tea are equally effective antioxidants. J Nutr (2001) 2.02
p53-dependent and -independent regulation of the death receptor KILLER/DR5 gene expression in response to genotoxic stress and tumor necrosis factor alpha. Cancer Res (1998) 2.02
Solution structure of the cellular factor BAF responsible for protecting retroviral DNA from autointegration. Nat Struct Biol (1998) 2.00
Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J Clin Oncol (1999) 1.92
Cloning, tissue distribution, genomic organization, and functional characterization of NBC3, a new member of the sodium bicarbonate cotransporter family. J Biol Chem (1999) 1.92
Differential roles of ERK and Akt pathways in regulation of EGFR-mediated signaling and motility in prostate cancer cells. Oncogene (2010) 1.91
Stable transgene expression in rod photoreceptors after recombinant adeno-associated virus-mediated gene transfer to monkey retina. Proc Natl Acad Sci U S A (1999) 1.89
Pathogenesis of type III hyperlipoproteinemia (dysbetalipoproteinemia). Questions, quandaries, and paradoxes. J Lipid Res (1999) 1.88
A precision measurement of the mass of the top quark. Nature (2004) 1.87
Cultivable anaerobic microbiota of severe early childhood caries. J Clin Microbiol (2011) 1.85
Increased corpus callosum size in musicians. Neuropsychologia (1995) 1.85
Cell separation on microfabricated electrodes using dielectrophoretic/gravitational field-flow fractionation. Anal Chem (1999) 1.84
Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer. J Clin Oncol (1999) 1.84
Diffusion-weighted MR imaging derived apparent diffusion coefficient is predictive of clinical outcome in primary central nervous system lymphoma. AJNR Am J Neuroradiol (2009) 1.83
Molecular cloning, chromosomal localization, tissue distribution, and functional expression of the human pancreatic sodium bicarbonate cotransporter. J Biol Chem (1998) 1.83
Dielectric properties of human leukocyte subpopulations determined by electrorotation as a cell separation criterion. Biophys J (1999) 1.82
Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus. J Clin Oncol (1998) 1.80
Evolution of maternofetal transport of immunoglobulins during human pregnancy. Am J Reprod Immunol (1996) 1.79
Association study of an SNP combination pattern in the dopaminergic pathway in paranoid schizophrenia: a novel strategy for complex disorders. Mol Psychiatry (2004) 1.79
Disease sequence from mutant rhodopsin allele to rod and cone photoreceptor degeneration in man. Proc Natl Acad Sci U S A (1998) 1.75
Phase II trial of preoperative radiation therapy and chemotherapy for patients with localized, resectable adenocarcinoma of the pancreas: an Eastern Cooperative Oncology Group Study. J Clin Oncol (1998) 1.72
Treatment tolerance of elderly cancer patients entered onto phase II clinical trials: an Illinois Cancer Center study. J Clin Oncol (1994) 1.71
Crystal structure of the 100 kDa arsenite oxidase from Alcaligenes faecalis in two crystal forms at 1.64 A and 2.03 A. Structure (2001) 1.71
Major factors influencing breastfeeding rates: Mother's perception of father's attitude and milk supply. Pediatrics (2000) 1.70
Differential analysis of human leukocytes by dielectrophoretic field-flow-fractionation. Biophys J (2000) 1.70
Mitochondrial dynamics regulates migration and invasion of breast cancer cells. Oncogene (2012) 1.69
effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers. Clin Pharmacol Ther (2006) 1.69
Methods for estimation of subsample time delays of digitized echo signals. Ultrason Imaging (1995) 1.69
Psychophysical evidence for rod vulnerability in age-related macular degeneration. Invest Ophthalmol Vis Sci (2000) 1.67
SUMO-1 marks the nuclear inclusions in familial neuronal intranuclear inclusion disease. Exp Neurol (2003) 1.66
Reduction to homozygosity involving p53 in esophageal cancers demonstrated by the polymerase chain reaction. Proc Natl Acad Sci U S A (1991) 1.62
Adjuvant therapy in rectal cancer: analysis of stage, sex, and local control--final report of intergroup 0114. J Clin Oncol (2002) 1.62
An efficient and cost-effective isotope labeling protocol for proteins expressed in Escherichia coli. J Biomol NMR (1998) 1.61
Sex but no hand difference in the isthmus of the corpus callosum. Neurology (1992) 1.60
Overexpression of Bcl-X(L) inhibits Ara-C-induced mitochondrial loss of cytochrome c and other perturbations that activate the molecular cascade of apoptosis. Cancer Res (1997) 1.60
Automation of X-ray crystallography. Nat Struct Biol (2000) 1.60
The Sweet syndrome during therapy with granulocyte colony-stimulating factor. Ann Intern Med (1992) 1.59
Block of calcium-activated potassium channels in mammalian arterial myocytes by tetraethylammonium ions. Am J Physiol (1991) 1.58
Effects of mutations in Pr160gag-pol upon tRNA(Lys3) and Pr160gag-plo incorporation into HIV-1. J Mol Biol (1997) 1.58
Low chloride stimulation of prostaglandin E2 release and cyclooxygenase-2 expression in a mouse macula densa cell line. J Biol Chem (2000) 1.57
p27Kip1 overexpression causes apoptotic death of mammalian cells. Oncogene (1997) 1.57
Loss of heterozygosity involving the APC and MCC genetic loci occurs in the majority of human esophageal cancers. Proc Natl Acad Sci U S A (1992) 1.56
Effect of combination antiretroviral therapy on T-cell immunity in acute human immunodeficiency virus type 1 infection. J Infect Dis (2000) 1.55
MiR-663, a microRNA targeting p21(WAF1/CIP1), promotes the proliferation and tumorigenesis of nasopharyngeal carcinoma. Oncogene (2012) 1.55
A MATE family multidrug efflux transporter pumps out fluoroquinolones in Bacteroides thetaiotaomicron. Antimicrob Agents Chemother (2001) 1.55
PCDH8, the human homolog of PAPC, is a candidate tumor suppressor of breast cancer. Oncogene (2008) 1.54
Vascular lesions in Chinese patients with transient ischemic attacks. Neurology (1997) 1.54
A brief dementia screener suitable for use by non-specialists in resource poor settings--the cross-cultural derivation and validation of the brief Community Screening Instrument for Dementia. Int J Geriatr Psychiatry (2010) 1.53
Regulation of Rad51 function by c-Abl in response to DNA damage. J Biol Chem (1998) 1.53
Perspectives on the new kidney disease education benefit: early awareness, race and kidney transplant access in a USRDS study. Am J Transplant (2012) 1.51
Glycosylation of shaker potassium channel protein in insect cell culture and in Xenopus oocytes. Biochemistry (1994) 1.51
Covalent inhibition revealed by the crystal structure of the caspase-8/p35 complex. Nature (2001) 1.51
26 S proteasome-mediated degradation of topoisomerase II cleavable complexes. J Biol Chem (2001) 1.50